Trial Profile
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Bial
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
- 26 Jun 2014 New trial record